Cromatina/Epigenética
Os inibidores de cromatina/epigenética são compostos que modulam a estrutura e função da cromatina ou interferem em modificações epigenéticas, como a metilação do DNA e a modificação de histonas. Esses inibidores são ferramentas essenciais para estudar a regulação da expressão gênica e o papel da epigenética em doenças como o câncer, distúrbios neurológicos e anomalias do desenvolvimento. Ao direcionar os processos epigenéticos, esses inibidores podem alterar os padrões de expressão gênica e oferecer novas vias terapêuticas. Na CymitQuimica, oferecemos uma ampla seleção de inibidores de cromatina/epigenética de alta qualidade para apoiar sua pesquisa em biologia molecular, genética e epigenética.
Subcategorias de "Cromatina/Epigenética"
Foram encontrados 2376 produtos de "Cromatina/Epigenética"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Cenacitinib
CAS:Cenacitinib is an effective inhibitor of Janus kinase (Janus kinase) and possesses anti-inflammatory activity.Fórmula:C19H19F2N7O3Cor e Forma:SolidPeso molecular:431.40NSD2-PWWP1-IN-2
CAS:<p>NSD2-PWWP1-IN-2 (compound 33) is a potent NSD2-PWWP1 inhibitor, exhibiting an IC50 value of 1.49 µM, indicating its potential utility in cancer research.</p>Fórmula:C29H30N4Cor e Forma:SolidPeso molecular:434.575(Rac)-RG108
CAS:<p>(Rac)-RG108 (NSC401077) is an inhibitor of DNMT1, effectively blocking DNA methyltransferases.</p>Fórmula:C19H14N2O4Cor e Forma:SolidPeso molecular:334.326LSD1/HDAC-IN-1
CAS:<p>LSD1/HDAC-IN-1 (compound 2) serves as an effective inhibitor of both HDAC and LSD1, demonstrating IC50 values of 0.125 nM, 0.373 nM, 0.0118 nM, 0.103 nM, and 0.571 μM for HDAC1, HDAC2, HDAC6, HDAC8, and LSD1 respectively. This compound plays a crucial role in cancer research.</p>Fórmula:C18H18N2O4SCor e Forma:SolidPeso molecular:358.41PRMT5-IN-1
CAS:<p>PRMT5-IN-1 is a covalent inhibitor of protein arginine methyltransferase 5 (PRMT5)(IC50 of 11 nM for PRMT5/MEP50).</p>Fórmula:C19H19ClN4O5Pureza:98%Cor e Forma:SolidPeso molecular:418.83Tyk2-IN-17
CAS:<p>Tyk2-IN-17 (compound 185) effectively inhibits TYK2 [1].</p>Fórmula:C20H20F2N8OCor e Forma:SolidPeso molecular:426.42JAK1/TYK2-IN-3
JAK1/TYK2-IN-3, orally active, selectively inhibits TYK2 (IC50: 6 nM), JAK1 (37 nM), JAK2 (140 nM), JAK3 (362 nM), and has anti-inflammatory effects.Cor e Forma:SolidSRI-43265
CAS:<p>SRI-43265 (compound 40) inhibits the dimerization of human antigen R protein (HuR), which is involved in cancer and inflammation pathogenesis [1].</p>Fórmula:C19H20N6OCor e Forma:SolidPeso molecular:348.4SCR-7952
CAS:<p>SCR-7952, a MAT2A inhibitor, is utilized in cancer research.</p>Fórmula:C19H15ClN4OCor e Forma:SolidPeso molecular:350.80Tyk2-IN-14
CAS:Tyk2-IN-14, a small molecule inhibitor of TYK2, is significant in treating inflammatory diseases and conditions linked to hypersecretion of IFNa and interferons [1].Fórmula:C22H21N9O2Cor e Forma:SolidPeso molecular:443.46Pim-1 kinase inhibitor 6
CAS:Pim-1 kinase inhibitor 6 (Compound 4d) is a robust inhibitor of Pim-1 kinase, demonstrating an IC 50 of 0.46 μM. It significantly exhibits cytotoxic effects on cancer cells [1].Fórmula:C21H10BrCl2N3Cor e Forma:SolidPeso molecular:455.13GDC-9918
CAS:<p>GDC-9918 (compound GDC-9918) is an inhibitor of Janus kinases.</p>Fórmula:C20H18F2N6O5SCor e Forma:SolidPeso molecular:492.46Tyk2-IN-20
CAS:Tyk2-IN-20 (Example 289) is an effective inhibitor of Tyk2 with an IC50 value below 5 nM. Additionally, it inhibits JAK1, JAK2, and JAK3 with IC50 values under 100 nM. This compound is utilized for the research of inflammatory diseases.Fórmula:C24H25N7O2Cor e Forma:SolidPeso molecular:443.50PRMT5-IN-21
<p>PRMT5-IN-21 (compound 1) is a potent inhibitor of cyclonucleoside PRMT5.</p>Fórmula:C18H18F2N6O3Cor e Forma:SolidPeso molecular:404.37G-631
CAS:<p>G-631 acts as a selective tankyrase inhibitor, effectively hindering tankyrase auto-PARsylation (poly ADP ribosylation) at an IC 50 of 7 nM and suppressing the Wnt signaling pathway. This compound also demonstrates favorable pharmacokinetic properties in mice.</p>Fórmula:C19H22F2N6O3Cor e Forma:SolidPeso molecular:420.41AJI-214
CAS:AJI-214 functions as a dual-target inhibitor that specifically blocks Aurora kinase A and JAK2. By directly inhibiting Aurora kinase A, AJI-214 prevents mitotic progression and cell polarity in T cells while concurrently suppressing JAK2 activation to reduce STAT3 phosphorylation. This inhibition decreases the differentiation of TH1 and TH17 cells. AJI-214 is utilized in research focused on the modulation of immune responses and the prevention of graft-versus-host disease (GVHD).Fórmula:C17H13ClFN5OCor e Forma:SolidPeso molecular:357.77Dot1L-IN-1
CAS:The Ki value of DOT1L-in-1 is 2pm.It is a highly effective, selective and novel Dot1L inhibitor.Fórmula:C32H36ClN9O2SPureza:98%Cor e Forma:SolidPeso molecular:646.21TY-011
CAS:<p>TY-011 is an inhibitor of Aurora A/B kinases. This compound induces DNA damage and cell apoptosis (Apoptosis) in human gastric cancer cells by promoting abnormal microtubule-kinetochore attachments, effectively suppressing cancer cell proliferation. The IC50 values for TY-011 in human gastric cancer cell lines range from 0.11-4.49 μM. It is utilized in research focused on gastric cancer.</p>Fórmula:C18H16ClN5Cor e Forma:SolidPeso molecular:337.81JAK3-IN-7
CAS:<p>JAK3-IN-7 is a potent and selective JAK3 inhibitor (IC50<0.01 μM) for the treatment of rejection in organ transplantation, graft-versus-host reaction after</p>Fórmula:C17H20N6OPureza:98.81%Cor e Forma:SolidPeso molecular:324.38DS44470011
CAS:<p>DS44470011 is an inhibitor of hypoxia-inducible factor prolyl hydroxylase (HIF-PHD) with oral bioavailability. It enhances the release of erythropoietin (EPO) from cells and is utilized in research related to renal anemia.</p>Fórmula:C21H19N3O4Cor e Forma:SolidPeso molecular:377.39IBL-302
CAS:IBL-302 (AMU302), an orally available dual-signaling inhibitor targeting PIM and PI3K/AKT/mTOR, is effective against breast cancer and neuroblastoma. It has shown in vivo efficacy in a nude mouse xenograft model by combating trastuzumab resistance. Additionally, IBL-302 augments the effectiveness of widely used cytotoxic chemotherapy drugs such as cisplatin, doxorubicin, and etoposide [1] [2] [3].Fórmula:C25H18FN5O4S3Cor e Forma:SolidPeso molecular:567.64BBC0403
CAS:<p>BBC0403 is a BRD2 inhibitor, inhibiting BRD2 and BRD2, and suppresses NF-κB and MAPK signaling pathways.</p>Fórmula:C21H22N2O5Pureza:98.15%Cor e Forma:SolidPeso molecular:382.41SE-7552
CAS:<p>SE-7552, a derivative of 2-(difluoromethyl)-1,3,4-oxadiazole (DFMO), serves as an orally active, highly selective non-hydroxamate HDAC6 inhibitor, boasting an IC50 of 33 nM. It exhibits over 850-fold selectivity against all other known HDAC isozymes. Demonstrating efficacy in vivo, SE-7552 effectively inhibits the growth of multiple myeloma. Additionally, it functions as an anti-obesity agent in diet-induced obese mice [1] [2].</p>Fórmula:C15H12F3N5OCor e Forma:SolidPeso molecular:335.28CBP/p300-IN-18
CBP/p300-IN-18 (compound 8) is a potent inhibitor of EP300/CBP HAT, acting on HAT EP300 (IC50: 0.056 μM) and LK2 H3K27 (IC50: 0.46 μM).Fórmula:C25H27FN4O3Cor e Forma:SolidPeso molecular:450.51AMI-408
CAS:<p>AMI-408 is a PRMT1 inhibitor that effectively reduces the levels of H4R3me2as in MLL-GAS7 leukemia cells.</p>Fórmula:C20H13Cl2N6NaO5SCor e Forma:SolidPeso molecular:543.32Aurora B inhibitor 1
CAS:<p>Aurora B inhibitor 1 is an Aurora B (Aurora-1) inhibitor (Ki <0.010 uM) with potential anticancer activity for cancer research.</p>Fórmula:C25H26ClF2N7O2Pureza:98.37%Cor e Forma:SolidPeso molecular:529.976K465
CAS:6K465 is a potent Aurora A kinase inhibitor that reduces c-MYC and N-MYC oncoproteins, showing antiproliferative effects in SCLC and breast cancer cell lines.Fórmula:C26H33ClFN9OPureza:99.78%Cor e Forma:SolidPeso molecular:542.05Balomenib
CAS:Balomenib is an inhibitor of the menin-MLL interaction, effectively blocking the men1-MLL4-43 interaction with an IC50 of less than 0.075 μM. It inhibits cell growth in MV4-11 (CC50 < 0.1 μM), MOLM-13 (CC50 0.1~0.5 μM), and HEK293 (CC50 < 2 μM) cells. Balomenib also exhibits antitumor activity.Fórmula:C33H34F3N7O2Cor e Forma:SolidPeso molecular:617.664RK-0080552
CAS:<p>RK-0080552 (RK-552) is an inhibitor of the NSD2 histone methyltransferase. It demonstrates significant cytotoxicity against multiple myeloma (MM) cells harboring the t(4;14) translocation. This compound suppresses the IRF4 gene and decreases the dimethylation of histone H3 at lysine 36. RK-0080552 holds promise for research in hematologic malignancies.</p>Fórmula:C12H6N6O2Cor e Forma:SolidPeso molecular:266.215HDAC3-IN-3
CAS:<p>HDAC3-IN-3 (compound 31), a potent inhibitor of HDAC3, holds potential for cancer research [1].</p>Fórmula:C26H22N4O2Cor e Forma:SolidPeso molecular:422.48BRD4 Inhibitor-32
CAS:<p>BRD4 Inhibitor-32 (example 15), a BRD4 inhibitor, is applicable in research pertaining to both acute and chronic kidney disease [1].</p>Fórmula:C26H25N3O3Cor e Forma:SolidPeso molecular:427.5Bromodomain inhibitor-13
CAS:Bromodomain Inhibitor-13 (Compound 1), an analog of PFI-3, is a bromodomain-containing protein (BCP) inhibitor. It specifically targets the bromodomains of SMARCA2, SMARCA4, and the first and second bromodomains of PB1 [PB1(5) and PB1(2)], with dissociation constants (KD) of 37, 53, 30, and 190 nM, respectively.Fórmula:C21H22N4O2Cor e Forma:SolidPeso molecular:362.43WIZ degrader 8
CAS:<p>WIZ degrader 8 (compound 10) is a potent and selective molecular glue degrader of the transcription factor WIZ, effectively inducing HbF expression. It promotes WIZ degradation and HbF induction, suggesting its potential use as an inhibitor for sickle cell disease.</p>Fórmula:C21H27N3O4Cor e Forma:SolidPeso molecular:385.457MAT2A-IN-16
CAS:<p>MAT2A-IN-16 is a MAT2A inhibitor that effectively suppresses the proliferation of MTAP-/-HCT-116 cells, with an IC50 value of 20 nM.</p>Fórmula:C23H17ClN6OCor e Forma:SolidPeso molecular:428.874JAK1-IN-9
CAS:JAK1-IN-9 (compound 23a) is a potent, selective inhibitor of JAK1, demonstrating an IC50 of 72 nM.Fórmula:C16H13IN6Cor e Forma:SolidPeso molecular:416.22Basroparib
CAS:Basroparib is an inhibitor of ribose polymerase (PARP) and has shown antitumour effects.Fórmula:C18H21F2N7O3Cor e Forma:SolidPeso molecular:421.4(Rac)-Nanatinostat
CAS:(Rac)-Nanatinostat ((Rac)-CHR-3996, example 44) is a potent HDAC inhibitor with an IC50 of less than 330 nM. It exhibits anticancer properties, effectively inhibiting the growth of HeLa, U937, and HUT cells.Fórmula:C20H19FN6O2Cor e Forma:SolidPeso molecular:394.402I-BET282E
I-BET282E inhibits eight BET bromodomains (pIC50 6.4-7.7) with selectivity for other bromodomain proteins.Fórmula:C26H34N4O7SCor e Forma:SolidPeso molecular:546.64AMPTX-1
CAS:AMPTX-1 is a molecular glue functioning as a potent, selective, and reversible covalent degrader of BRD9 by recruiting it to the E3 ligase DCAF16.Fórmula:C42H53N5O4Cor e Forma:SolidPeso molecular:691.901CEE321
CAS:<p>CEE321 is an effective pan-JAK inhibitor with an IC50 of 54 nM. It effectively inhibits biomarkers associated with atopic dermatitis.</p>Fórmula:C18H16ClN5OCor e Forma:SolidPeso molecular:353.806XY153
XY153 (8l) is a BD2 selective BET inhibitor targeting BRD4, 3 & 2 with IC50s: 0.79, 5.31 & 5.09 nM, useful in acute myeloid leukemia & cancer research.Fórmula:C33H34FN3O4Cor e Forma:SolidPeso molecular:555.64B026
CAS:<p>B026: Oral p300/CBP HAT inhibitor, IC50: p300 1.8 nM, CBP 9.5 nM; targets AR+ prostate cancer cells.</p>Fórmula:C27H23F4N5O4Cor e Forma:SolidPeso molecular:557.5SIRT1-IN-5
CAS:SIRT1-IN-5 (215) is a modulator of NAD-dependent deacetylase SIRT1 with potential applications in cancer and cellular signaling research.Fórmula:C21H17N3O3SPureza:99.97%Cor e Forma:SolidPeso molecular:391.44GSK3368715
CAS:GSK3368715 is an orally active, reversible, and S-adenosyl-L-methionine (SAM) uncompetitive type I protein arginine methyltransferases (PRMTs) inhibitor (IC50sFórmula:C20H38N4O2Pureza:98%Cor e Forma:SolidPeso molecular:366.54FT001
CAS:<p>FT001: Oral BET Bromodomain inhibitor, IC50=0.46μM, suppresses MYC, anti-cancer, effective in vitro/vivo.</p>Fórmula:C25H29N3O4SPureza:99.9%Cor e Forma:SolidPeso molecular:467.58MAO A/HDAC-IN-1
<p>MAO A/HDAC-IN-1 is an effective monoamine oxidase A (MAO A) and HDAC dual inhibitor, which can be used for glioma research.</p>Fórmula:C21H24ClN3O3Cor e Forma:SolidPeso molecular:401.89MDH1/2-IN-1
CAS:<p>MDH1/2-IN-1 is an MDH1/2 inhibitor with IC50 values of 1.07 nM and 1.06 nM, respectively. It suppresses mitochondrial respiration and the HIF-1α pathway. MDH1/2-IN-1 exhibits significant antitumor potential and offers new avenues for developing drugs targeting cancer metabolism.</p>Fórmula:C25H33NO4Cor e Forma:SolidPeso molecular:411.534EED ligand 1
<p>EED ligand 1: potent PRC2 inhibitor targeting EED subunit.</p>Fórmula:C19H19FN8OCor e Forma:SolidPeso molecular:394.41LSD1/2-IN-4
LSD1/2-IN-4, a PCPA derivative, inhibits LSD1 (Ki 0.11 μM) & LSD2 (Ki 130 μM), potentially useful in T-cell leukemia research.Fórmula:C9H8BrF2NCor e Forma:SolidPeso molecular:248.07PARP-1-IN-1
<p>PARP-1-IN-1: Selective, oral PARP-1 inhibitor with 0.96 nM IC50; well-tolerated and effective in single-dose MDA-MB-436 model.</p>Fórmula:C23H25FN4OCor e Forma:SolidPeso molecular:392.47PARP-1/HDAC-IN-1
CAS:<p>PARP-1/HDAC-IN-1 is a PARP-1 and HDAC6 inhibitor with anticancer, antimigratory, and antiangiogenic activities and is used in tumor research.</p>Fórmula:C22H18N4O4Pureza:95.94%Cor e Forma:SolidPeso molecular:402.4HDAC1-IN-8
CAS:<p>HDAC1-IN-8 (compound 5c) is a potent and selective HDAC1 inhibitor, with IC50 values of 11.94 µM for HDAC1, 22.95 µM for HDAC6, and greater than 500 µM for HDAC8. It exhibits antiproliferative activity, induces cell cycle arrest in G1 and G2/M phases, and triggers autophagy (autophagy). Additionally, HDAC1-IN-8 demonstrates anticancer properties and holds potential for lung cancer research.</p>Fórmula:C22H24N2O4Cor e Forma:SolidPeso molecular:380.437BET-IN-8
BET-IN-8 (Compound 27) is a potent inhibitor of BET (Ki: 0.83 μM, Kd: 0.571 μM), which ameliorates LPS-induced sepsis in vivo.BET-IN-8 has shown potential inFórmula:C22H21N3O4SCor e Forma:SolidPeso molecular:423.48PF-06726304 acetate
CAS:<p>PF-06726304 acetate is a selective inhibitor of EZH2, with robust antitumor growth activity.</p>Fórmula:C24H25Cl2N3O5Pureza:98%Cor e Forma:SolidPeso molecular:506.3815:0 PG sodium
CAS:15:0 PG sodium serves as an activator for the Protein Kinase C family and is an anionic phospholipid located in the membranes of mitochondria and microsomes. It plays a crucial role in the composition of pulmonary surfactants, especially within the membrane of the pulmonary lamellar bodies.Fórmula:C36H70NaO10PCor e Forma:SolidPeso molecular:716.90DS17701585
DS17701585: Oral EP300/CBP inhibitor; potent on CBP, EP300, H3K27, & SOX2; useful for cancer research.Fórmula:C24H26N4O5SCor e Forma:SolidPeso molecular:482.55BRD4-BD1/2-IN-2
CAS:BRD4-BD1/2-IN-2 inhibits BRD4 BD1/BD2 with IC50 <300 nM/<0.5 nM (WO2021233371A1).Fórmula:C30H33N5O4Cor e Forma:SolidPeso molecular:527.61HDAC2-IN-1
HDAC2-IN-1 is an oral HDAC2 inhibitor (IC50: 0.5 μM), crosses the blood-brain barrier, and inhibits HDAC1 and HDAC8.Fórmula:C22H23ClN4OSCor e Forma:SolidPeso molecular:426.96HDAC-IN-33
HDAC-IN-33 inhibits HDAC1/2/6 (IC50: 24/46/47 nM), exhibits potent antitumor activity in vitro and in vivo, and activates antitumor immunity.Fórmula:C21H25N3O3Cor e Forma:SolidPeso molecular:367.44BRD4-IN-7
CAS:<p>BRD4-IN-7, also known as compound 120, acts as a BRD4 inhibitor.</p>Fórmula:C29H24F2N4O3Cor e Forma:SolidPeso molecular:514.52PARP10/15-IN-1
PARP10/15-IN-1 (compound 8l) is a dual PARP10 and PARP15 inhibitor with IC50s of 160 nM and 370 nM, respectively. It can be used in cancer research[1].Fórmula:C13H10N2O3SCor e Forma:SolidPeso molecular:274.3(1-Nitroethene-1,2-diyl)dibenzene
CAS:(1-Nitroethene-1,2-diyl)dibenzene (alpha-Nitrostilbene; α-Nitrostilbene) serves as an inhibitor of protein arginine methyltransferase 1 (PRMT1; histone H4 methylation assay with an IC50 of 11 μM). At concentrations of 10 and 100 μM, it also inhibits histone H4 methylation caused by PRMT8 but does not affect methylation of histone H3.1 induced by CARM1 or Set7/9.Fórmula:C14H11NO2Cor e Forma:SolidPeso molecular:225.24NMDAR/HDAC-IN-1
<p>Compound 9d is a dual NMDAR and HDAC inhibitor with high NMDAR affinity (Ki=0.59 μM) and inhibits HDAC1-3,6,8; crosses the blood-brain barrier.</p>Fórmula:C22H28N2O3Cor e Forma:SolidPeso molecular:368.47RK-582
CAS:RK-582: oral spiroindolinone tankyrase inhibitor, halts colon cancer growth in COLO-320DM mouse model.Fórmula:C27H35FN6O3Cor e Forma:SolidPeso molecular:510.6DCHC
CAS:<p>DCHC is an activator of SIRT1, but it does not induce SIRT1 expression. This compound can be utilized in studies related to mitochondrial damage.</p>Fórmula:C15H8Cl2O3Cor e Forma:SolidPeso molecular:307.128HDAC/HSP90-IN-4
HDAC/HSP90-IN-4 inhibits HDAC (20 IC50=194nM, 26 IC50=360nM) & HSP90α (20 IC50=153nM, 26 IC50=77nM), affects cancer cell survival and invasion.Fórmula:C20H23N3O6Cor e Forma:SolidPeso molecular:401.15869CM-414
CAS:<p>CM-414: HDAC/PDE5 inhibitor, targeting Alzheimer’s, IC50s: PDE5 (60 nM), HDAC1/2/3/6. Reduces Aβ, pTau in mice, boosts cognition.</p>Fórmula:C23H29N5O4Pureza:98%Cor e Forma:SolidPeso molecular:439.51AZ0108
CAS:<p>AZ0108, an oral PARP1,2,6 inhibitor, selectively blocks centrosome clustering, is viable for in vivo studies, and doesn't inhibit PARP3/TNKS1.</p>Fórmula:C24H20F4N6O2Cor e Forma:SolidPeso molecular:500.45GNE-886
CAS:<p>GNE-886 has a wide range of applications in life science related research.</p>Fórmula:C28H30N6O3Pureza:98%Cor e Forma:SolidPeso molecular:498.59LSD1/2-IN-3
LSD1/2-IN-3 selectively inhibits LSD1 (Ki 11 nM) over LSD2 (Ki 7 μM), and hinders tumor stem cell proliferation.Fórmula:C9H8BrF2NCor e Forma:SolidPeso molecular:248.07AZ13824374
AZ13824374: potent, selective ATAD2 inhibitor; anti-proliferative in breast cancer; pIC50: FRET 8.2, NanoBRET 6.2.Fórmula:C30H39FN8O2Cor e Forma:SolidPeso molecular:562.68RL5a
CAS:<p>RL5a (compound C23) is a novel inhibitor of SETD8.</p>Fórmula:C17H19N3OCor e Forma:SolidPeso molecular:281.35LSD1-IN-17
<p>LSD1-IN-17, a potent LSD1/CoREST/MAO inhibitor, IC50: 0.005/0.028/0.820 μM; hinders LNCaP prostate cancer cell growth, IC50: 17.2 μM.</p>Fórmula:C20H18N2OSCor e Forma:SolidPeso molecular:334.43HIF-1/2α-IN-1
HIF-1/2α-IN-1, an orally active compound, functions as an inhibitor of HIF-2α.Fórmula:C17H16N6O4Cor e Forma:SolidPeso molecular:368.35PAD2-IN-1 hydrochloride
PAD2-IN-1 hydrochloride: potent, selective PAD2 inhibitor; 95x less on PAD4, 79x less on PAD3; benzimidazole derivative.Fórmula:C25H30ClFN6O3Cor e Forma:SolidPeso molecular:517HDAC-IN-32
HDAC-IN-32, potent inhibitor: IC50—HDAC1 (5.2 nM), HDAC2 (11 nM), HDAC6 (28 nM). Effective anti-tumor and immunity-boosting traits.Fórmula:C20H23N3O3Cor e Forma:SolidPeso molecular:353.41KDOAM-25 citrate
CAS:KDOAM-25 citrate inhibits KDM5A/B/C/D (IC50: 71, 19, 69, 69 nM); boosts H3K4 methylation, hinders MM1S cell growth. [1]Fórmula:C21H33N5O9Pureza:98%Cor e Forma:SolidPeso molecular:499.51STR-V-53
CAS:<p>STR-V-53, an HDAC inhibitor (IC50 in nM), increases histone acetylation in tumor cells by inhibiting these enzymes, thereby regulating gene expression. STR-V-53 inhibits tumor growth and induces apoptosis [1].</p>Fórmula:C21H30N4O8Cor e Forma:SolidPeso molecular:466.48Enzomenib
CAS:<p>Enzomenib (DSP5336), a menin protein inhibitor encoded by the multiple endocrine neoplasia (MEN) gene, blocks the interaction between menin protein and mixed lineage leukemia (MLL) fusion proteins. This compound is utilized in researching hematological malignancies.</p>Fórmula:C33H43FN6O3Cor e Forma:SolidPeso molecular:590.73HDAC6-IN-13
<p>HDAC6-IN-13: potent, selective HDAC6 inhibitor; oral; IC50=0.019μM; targets HDAC1/2/3; crosses blood-brain barrier; anti-inflammatory.</p>Fórmula:C23H22N4OCor e Forma:SolidPeso molecular:370.45MI-1481
CAS:MI-1481: potent MML1 inhibitor, IC50 3.6 nM; disrupts menin-MLL1, active in MLL leukemia.Fórmula:C29H30F3N7O2SPureza:98%Cor e Forma:SolidPeso molecular:597.65HDAC-IN-27
HDAC-IN-27 is a potent and orally active inhibitor of HDAC Class I (0.43 nM - 3.01 nM for HDAC1-3).Fórmula:C20H22N4O2Cor e Forma:SolidPeso molecular:350.41MMSET-IN-1
CAS:MMSET-IN-1 is an inhibitor of multiple myeloma SET domain (MMSET, aka NSD2/WHSC1) .Fórmula:C18H29N7O5Pureza:98%Cor e Forma:SolidPeso molecular:423.47Equisetin
CAS:Equisetin: a QSI from Fusarium equiseti, curbs P. aeruginosa virulence, fights Gram-positive bacteria & HIV-1 integrase; not antibacterial to Gram-negative.Fórmula:C22H31NO4Pureza:98%Cor e Forma:SolidPeso molecular:373.49PRMT5-IN-50
CAS:<p>PRMT5-IN-50 is an orally active selective inhibitor of PRMT5, demonstrating good metabolic stability and low clearance in human liver microsomes. It inhibits SDMA/HCT116-MTAPdel and SDMA/HCT116-MTAPwt with IC50 values for symmetric arginine methylation inhibition at 1.0 and 536 nM, respectively, and antiproliferative IC50 values at 19 and 1620 nM, respectively. Additionally, PRMT5-IN-50 suppresses tumor growth in mice.</p>Fórmula:C26H23F3N6OCor e Forma:SolidPeso molecular:492.496AZ-3
CAS:AZ-3 is a potent and selective JAK1 inhibitor (IC50: 34 nM).Fórmula:C20H28FN7Pureza:98%Cor e Forma:SolidPeso molecular:385.48SGC6870N
CAS:<p>SGC6870N is inactive against PRMT6 and can be used as a negative control. It is the inactive enantiomer of SGC6870.</p>Fórmula:C23H21BrN2O2SPeso molecular:469.39MS8815
CAS:MS8815 is a selective EZH2 PROTAC degrader with IC50 of 8.6 nM, used in triple-negative breast cancer research.Fórmula:C65H87N9O8SCor e Forma:SolidPeso molecular:1154.51DS-9300
CAS:DS-9300, an orally administered potent and selective inhibitor of EP300/CBP HAT, exhibits a significant inhibitory activity with an IC50 value of 28 nM.Fórmula:C25H26F3N5O3Cor e Forma:SolidPeso molecular:501.50HuR degrader 2
CAS:<p>HuRdegrader 2 (Compound 3) is a molecular glue that targets and degrades the RNA-binding protein Hu antigen R (HuR), achieving 30% degradation at 0.1 μM. It inhibits the proliferation of Colo-205 cancer cells with an IC50 of ≤200 nM. HuRdegrader 2 also shows high affinity for cereblon with an HTRF ratio < 0.02.</p>Fórmula:C20H15N3O3Peso molecular:345.35NPC26
CAS:<p>NPC26 is a small molecule that disrupts mitochondrial function and exhibits antitumor activity. It shows significant antiproliferative and cytotoxic effects on CRC cell lines (HCT-116, DLD-1, and HT-29). NPC26 induces mitochondrial permeability transition pore (mPTP) opening, generates reactive oxygen species (ROS), and triggers cell death. Additionally, NPC26 kills CRC cells by activating the AMP-activated protein kinase (AMPK) signaling pathway.</p>Fórmula:C19H23N3O5S2Cor e Forma:SolidPeso molecular:437.533Octyl-α-hydroxyglutarate
CAS:<p>Octyl-α-hydroxyglutarate (octyl-2-HG) enhances histone methylation and boosts the viability of LMP1-negative nasopharyngeal carcinoma (NPC) cells.</p>Fórmula:C13H24O5Peso molecular:260.33BRD4/NAMPT-IN-1
CAS:BRD4/NAMPT-IN-1 (Compound A2) exhibits strong inhibitory effects on NAMPT and BRD4, with IC50 values of 35 nM (NAMPT) and 58 nM (BRD4). This compound significantly suppresses the growth and migration of liver cancer cells while promoting apoptosis. Additionally, BRD4/NAMPT-IN-1 demonstrates potent anticancer activity in HCCLM3 xenograft mouse models without noticeable toxicity.Fórmula:C30H30ClN7O2SPeso molecular:588.12KH-259
KH-259: potent, selective CNS-penetrant HDAC6 inhibitor with 0.26 μM IC50; shows antidepressant effects in mice.Fórmula:C20H25N3O2Cor e Forma:SolidPeso molecular:339.43BRD4 Inhibitor-17
BRD4 Inhibitor-17: Potent with 0.33 μM IC50; modulates gene expression, may counter arsenic toxicity.Fórmula:C16H16FN3O3SCor e Forma:SolidPeso molecular:349.38Pim-1 kinase inhibitor 3
CAS:<p>Pim-1 kinase inhibitor 3 (Compound H5) is a potent inhibitor of Pim-1 kinase, demonstrating an inhibitory concentration (IC50) of 35.13 nM [1].</p>Fórmula:C20H25N3O2Cor e Forma:SolidPeso molecular:339.43JAK2 JH2 binder-1
CAS:<p>JAK2 JH2 binder-1: potent, selective, Ki=37.1 nM, potential for studying myeloproliferative neoplasms.</p>Fórmula:C29H25N7O6SCor e Forma:SolidPeso molecular:599.62HDAC6-IN-12
HDAC6-IN-12 is a potent inhibitor of HDAC6 that binds in the DNA chain, causing DNA damage and exhibiting anticancer effects that can be used in cancer researchFórmula:C24H39F2N3O5Cor e Forma:SolidPeso molecular:487.58Triciferol
CAS:Triciferol is a VDR agonist and HDAC antagonist with 1,25D-like potency, affecting gene targets and tubulin, and shows anti-cancer effects in vitro. IC50=87nM.Fórmula:C26H39NO4Cor e Forma:SolidPeso molecular:429.591PARP7-IN-23
CAS:<p>PARP7-IN-23 (compound 56) is a potent PARP7 inhibitor with an EC50 of 0.915 nM for pSTAT1 in NCI-H1373 cells, indicating its potential for cancer research.</p>Fórmula:C27H22F7N5O3Cor e Forma:SolidPeso molecular:597.484HDAC6-IN-9
CAS:HDAC6-IN-9 is a γ-secretase modulator that can significantly reduce the level of Aβ42 in mouse brain and can be used to study neurological diseases.Fórmula:C19H16N2O3Pureza:98.84%Cor e Forma:SolidPeso molecular:320.34AR/BET protein degrader-1
CAS:AR/BET protein degrader-1 (Compound 149) is a dual-targeting protein degrader of Androgen Receptor and BET (bromodomain and extra-terminal domain), suitable for cancer research.Fórmula:C43H44N6O5Peso molecular:724.85O-Desmethyl Midostaurin
CAS:O-Desmethyl Midostaurin is the active Midostaurin metabolite via cytochrome P450 liver enzyme metabolism.Fórmula:C34H28N4O4Pureza:98%Cor e Forma:SolidPeso molecular:556.61CBP/p300-IN-16
<p>CBP/p300-IN-16 (compound 1) is a potent inhibitor of EP300/CBP HAT, acting on HAT EP300 (IC50: 0.61 μM) and LK2 H3K27 (IC50: 2.24 μM).</p>Fórmula:C26H31N3O4Cor e Forma:SolidPeso molecular:449.54NVS-BPTF-1
CAS:<p>NVS-BPTF-1 is a specific inhibitor of bromodomain and PHD finger containing transcription factor (BPTF), exhibiting a dissociation constant (K_D) of 71 nM [1].</p>Fórmula:C26H28FN7O3SCor e Forma:SolidPeso molecular:537.61CFT8634
CAS:CFT8634 degrades BRD9, for synovial sarcoma and SMARCB1 tumor research, from patent WO2021178920A1.Fórmula:C37H45F3N6O5Cor e Forma:SolidPeso molecular:710.79EBET-590
CAS:EBET-590 is a BET inhibitor utilized in cancer research.Fórmula:C26H26N4O3Peso molecular:442.51CARM1-IN-3 dihydrochloride
CARM1-IN-3 dihydrochloride (17b) is a potent CARM1 inhibitor (IC50: 0.07 μM) with selectivity over CARM3 (IC50 >25 μM).Fórmula:C24H34Cl2N4O2Cor e Forma:SolidPeso molecular:481.46PARP14 inhibitor 1
CAS:<p>PARP14 inhibitor1 (compound Q22) is a selective inhibitor of PARP14 with an IC50 of 5.52 nM. It also exhibits anti-inflammatory properties and has a half-life of 182 minutes in mouse liver microsomes. This compound is applicable for atopic dermatitis research.</p>Fórmula:C23H27FN4O3Cor e Forma:SolidPeso molecular:426.484EN884
CAS:EN884 is a BRD4 degrader that functions through an SKP1 and proteasome-dependent degradation pathway. It is utilized in the synthesis of proteolysis-targeting chimeras (PROTAC).Fórmula:C14H18N2OPeso molecular:230.31SMARCA2-IN-6
CAS:<p>SMARCA2-IN-6 is a potent inhibitor of SMARCA2 (also known as BRM), exhibiting an IC50 of less than 5 nM against both SMARCA2 and SMARCA4. Additionally, this compound suppresses the expression of the KRT80 gene in H1299 cells with an IC50 of 26 nM and inhibits the proliferation of SKMEL5 cells carrying a BRG1 mutation with an IC50 value of 13 nM.</p>Fórmula:C10H8ClF2N5OSCor e Forma:SolidPeso molecular:319.72JAK3 covalent inhibitor-1
CAS:<p>JAK3 Covalent Inhibitor-1 is a compound characterized by its potent and selective inhibition of Janus kinase 3 (JAK3), possessing an IC50 of 11 nM and</p>Fórmula:C22H17FN6O2SPureza:98%Cor e Forma:SolidPeso molecular:448.47GSK789
CAS:<p>GSK789 is a selective inhibitor of the first bromodomains (BD1) of the bromo and extra terminal domain (BET) proteins.</p>Fórmula:C26H33N5O3Cor e Forma:SolidPeso molecular:463.57BRD-7880
CAS:BRD-7880 is a potent and highly specific inhibitor of aurora kinases B and C.Fórmula:C32H38N4O7Cor e Forma:SolidPeso molecular:590.67BRD4 D1-IN-2
<p>BRD4 D1-IN-2 (compound 26), a BRD4 D1 inhibitor, IC50 <0.092 μM, 15 nM affinity, >500x selectivity over BRD2 D1/BRD4 D2.</p>Fórmula:C33H39F3N6OCor e Forma:SolidPeso molecular:592.7LSD1-IN-35
CAS:<p>LSD1-IN-35 (Compound Z-1) is a selective inhibitor of LSD1, exhibiting an IC50 of 108 nM. This compound inhibits the demethylation of H3K4me1/2 and acts as an immunomodulator. Additionally, LSD1-IN-35 enhances the responsiveness of gastric cancer cells to T-cell killing by reducing PD-L1 expression, thereby weakening the PD-1/PD-L1 interaction.</p>Fórmula:C25H26N4O2SCor e Forma:SolidPeso molecular:446.57TDI-015051
CAS:TDI-015051 is an orally active inhibitor of SARS-CoV-2 non-structural protein 14 (SARS-CoV-2 NSP14) with an IC50 of ≤0.15 nM. It effectively inhibits SARS-CoV-2 NSP14 in Huh-7.5 cells (EC50=11.4 nM) and A549 cells expressing ACE2-TMPRSS2 (EC50=64.7 nM). Additionally, TDI-015051 suppresses other coronaviruses such as α-hCoV-NL63, α-hCoV-229E, and β-hCoV-MERS with IC50 values of 1.7, 2.6, and 3.6 nM, respectively. This compound inhibits viral RNA methylation and replication by binding to a stable SAH-cap pocket and demonstrates anti-infection activity in mouse models.Fórmula:C22H22FN5O4SCor e Forma:SolidPeso molecular:471.505SMARCA2/4-ligand-5
CAS:<p>SMARCA2/4-ligand-5 is the target protein ligand of PROTAC SMARCA2/4 degrader-37 (Example 4). PROTAC SMARCA2/4 degrader-37 (Example 4) is a PROTAC degrader of SMARCA2/4, with an IC50 value of ≤0.1 μM.</p>Fórmula:C20H13ClN4O3Cor e Forma:SolidPeso molecular:392.795PARP1-IN-29
CAS:<p>PARP1-IN-29 is an orally active PARP-1 inhibitor with an IC50 of 6.3 nM. When labeled with [18F], PARP1-IN-29 can be utilized for positron emission tomography (PET) imaging, specifically targeting PARP-1 in tumors. This compound is useful in oncology and imaging studies, particularly for detecting PARP-1 activity in cancer.</p>Fórmula:C18H16FN3O2Cor e Forma:SolidPeso molecular:325.34XP5
<p>XP5 is an oral HDAC6 inhibitor, potent against cancer cells, including YCC3/7 (IC50=31 nM to 2.31 μM).</p>Fórmula:C19H25N3O5SCor e Forma:SolidPeso molecular:407.48BRD4 Inhibitor-33
CAS:<p>BRD4 Inhibitor-33 (example 13), a potent inhibitor of BRD4, is applicable in research related to both acute and chronic kidney diseases [1].</p>Fórmula:C24H20N4O2Cor e Forma:SolidPeso molecular:396.44Menin-MLL inhibitor 4
CAS:Menin-MLL inhibitor 4 has antitumor activity.Menin-MLL inhibitor 4 is an inhibitor of Menin- MLL (mixed-lineage leukemia protein) interaction .Fórmula:C32H38FN7O3Pureza:98%Cor e Forma:SolidPeso molecular:587.69(2S,3R)-LP99
CAS:(2S,3R)-LP99 is a less active enantiomer of LP99.Fórmula:C26H30ClN3O4SPureza:98%Cor e Forma:SolidPeso molecular:516.05KAT6A-IN-2
CAS:KAT6A-IN-2 (compound 7) is an inhibitor of KAT6A.Fórmula:C23H29N5O5SCor e Forma:SolidPeso molecular:487.57PRMT5-IN-1 hydrochloride
PRMT5 IN-1 hydrochloride is a potent PRMT5 inhibitor (IC50: 11 nM), forms covalent adduct with C449, and converts to an aldehyde in vivo.Fórmula:C19H20Cl2N4O5Cor e Forma:SolidPeso molecular:455.29QCA570
CAS:QCA570 is an effective BET degrader based on PROTAC (IC50: 10 nM for BRD4 BD1 Protein).Fórmula:C39H33N7O4SPureza:98%Cor e Forma:SolidPeso molecular:695.79MS8511
CAS:<p>MS8511: Selective, irreversible G9a/GLP inhibitor. IC50: 100 nM (G9a), 140 nM (GLP). Lowers H3K9me2, anti-proliferative. Useful in cancer/AD/PWS research.</p>Fórmula:C28H41N5O3Cor e Forma:SolidPeso molecular:495.66INCB054329
CAS:INCB054329 is a BET inhibitor targeting BRD2/3/4 and BRDT with IC50s ranging from 1-119 nM.Fórmula:C19H16N4O3Pureza:99.52%Cor e Forma:SolidPeso molecular:348.36BAY-3827
CAS:BAY-3827 is an AMPK inhibitor with antiproliferative activity and antitumor activity. BAY-3827 inhibits the phosphorylation of acetyl CoA carboxylase 1.Fórmula:C27H25FN6OPureza:99.90%Cor e Forma:SolidPeso molecular:468.53LLY-283
CAS:LLY-283, PRMT5 inhibitor, IC50 22 nM, Kd 6 nM, oral, selective, with antitumor effects.Fórmula:C17H18N4O4Pureza:99.49%Cor e Forma:SolidPeso molecular:342.35Pocenbrodib
CAS:<p>Pocenbrodib (FT-7051) is a potent inhibitor of the bromodomain of the CBP/p300 family with potential antitumour activity and is palatable for cancer research.</p>Fórmula:C28H32FN3O6Pureza:98.48% - 99.54%Cor e Forma:SolidPeso molecular:525.57AMG-193
CAS:AMG-193 is an inhibitor of the MTA-PRMT5 complex and is used in the study of cancer, respiratory diseases and digestive disorders.Fórmula:C22H19F3N4O3Pureza:99.52%Cor e Forma:SolidPeso molecular:444.41YTH-IN-1
CAS:YTH-IN-1 is an inhibitor of the five YTH structural domains in the human.The YTH family of proteins is an N 6-methyladenosine (m6A) reader in gene expression.Fórmula:C18H24N6O3Pureza:98.46% - 99.94%Cor e Forma:SolidPeso molecular:372.42EZM0414
CAS:EZM0414 is a potent, selective, orally bioavailable inhibitor of SETD2 with IC50 of 18 nM in SETD2 biochemical assay and IC50 of 34 nM in a cellular assay.Fórmula:C22H29FN4O2Pureza:99.58%Cor e Forma:SolidPeso molecular:400.49ORIC-944
CAS:<p>ORIC-944 is an orally available, selective variant of PRC2 with anticancer activity for the study of prostate cancer.</p>Fórmula:C26H25FN6OPureza:98.08%Cor e Forma:SolidPeso molecular:456.52DN02
<p>DN02: a potent, selective BRD8(1) bromodomain probe; Ki=32 nM; 30x more affine than BRD8(2).</p>Fórmula:C22H24FN3O3Pureza:98.22% - 99.74%Cor e Forma:SolidPeso molecular:397.44GSK3368715 dihydrochloride
CAS:GSK3368715 dihydrochloride (EPZ019997 dihydrochloride) is a PRMTs inhibitor , with anticancer activity, for the study of advanced solid tumors.Fórmula:C20H40Cl2N4O2Pureza:99.66% - 99.66%Cor e Forma:SolidPeso molecular:439.46Sinefungin
CAS:Sinefungin (Adenosyl-Ornithine) is an effective inhibitor of virion mRNA(guanine-7-)-methyltransferase, mRNA(nucleoside-2'-)-methyltransferase, and viralFórmula:C15H23N7O5Pureza:98.12%Cor e Forma:SolidPeso molecular:381.39JDTic
CAS:JDTic, a 4-phenylpiperidine derivative distantly related to analgesics like meperidine and ketobemidone and more closely to the mu opioid antagonist alvimopan, exhibits a notably long duration of action, maintaining effects in animals for weeks following a single dose. This duration is not due to irreversible binding to the kappa opioid receptor but rather to altered activity of c-Jun N-terminal kinases. As a highly selective antagonist for the κ-opioid receptor, without influencing the μ- or δ-opioid receptors, JDTic has shown potential in animal studies for producing antidepressant and anxiolytic effects. It also demonstrates promise in treating addiction to substances such as cocaine and morphine, distinguishing itself structurally from other kappa antagonists like norbinaltorphimine.Fórmula:C28H39N3O3Cor e Forma:SolidPeso molecular:465.63BRD0639
CAS:BRD0639 is a first-in-class PRMT5-substrate interaction inhibitor for PBM-dependent PRMT5 activity studies.Fórmula:C21H22ClN5O4SPureza:99.85%Cor e Forma:SolidPeso molecular:475.95EHMT2-IN-2
CAS:EHMT2-IN-2 Used in the research of blood disease or cancer. EHMT2-IN-2 is a potent EHMT inhibitor, with IC50s of all <100 nM for EHMT1 peptide, EHMT2 peptide and cellular EHMT2.Fórmula:C21H22N6OCor e Forma:SolidPeso molecular:374.44(8R,9S)-Talazoparib
CAS:(8R,9S)-Talazoparib is Talazoparib enantiomer , less active than Talazoparib on the inhibition of PARP1 (IC50: 144 nM).Fórmula:C19H14F2N6OCor e Forma:SolidPeso molecular:380.35BD-9136
<p>BD-9136, a highly selective BRD4 degrader, demonstrates the capability to inhibit tumor growth without inducing adverse effects in mice, showing potential for</p>Fórmula:C44H44N10O5SPureza:98%Cor e Forma:SolidPeso molecular:824.95HJB97
CAS:HJB97 is used for the design of potential PROTAC BET degrader. It also has antitumor activity. HJB97 is a high-affinity inhibitor of BET (Kis: 0.9 nM (BRD2 BD1), 0.27 nM (BRD2 BD2), 0.18 nM (BRD3 BD1), 0.21 nM (BRD3 BD2), 0.5 nM (BRD4 BD1), 1.0 nM (BRD4 BD2), respectively).Fórmula:C26H28N8O3Pureza:98%Cor e Forma:SolidPeso molecular:500.55Ref: TM-T15484
Produto descontinuado(3R,4S)-Tofacitinib
CAS:(3R,4S)-Tofacitinib, the less active enantiomer of Tofacitinib, is a JAK3 inhibitor with an IC50 of 1 nM.Fórmula:C16H20N6OPureza:98%Cor e Forma:SolidPeso molecular:312.37CARM1-IN-1 hydrochloride
CAS:CARM1-IN-1 hydrochloride is a potent and selective inhibitor of CARM1 (IC50: 8.6 μM) with minimal inhibition of PRMT1 and SET7.Fórmula:C26H22Br2ClNO3Cor e Forma:SolidPeso molecular:591.7220-HETE
CAS:<p>20-HETE is a CYP450 product, vasoconstrictor, modulates K+ channels, affects NADPH, ROS, NF-κB, NO synthase, and cell apoptosis/proliferation.</p>Fórmula:C20H32O3Pureza:99.79%Cor e Forma:SolidPeso molecular:320.47Cercosporin
CAS:<p>Cercosporin, produced by the plant pathogen Cercospora kikuchii and the elsinochromes, is a potent photosensitizer with a short activation wavelength. Cercosporin contains perylene quinone structural features essential for PKC activity (IC50: 0.6-1.3 μM).</p>Fórmula:C29H26O10Pureza:98%Cor e Forma:SolidPeso molecular:534.51HIF-PHD-IN-1
CAS:<p>HIF-PHD-IN-1 is a pharmacological compound that acts as an orally active inhibitor of the hypoxia-inducible factor prolyl hydroxylase domain (HIF-PHD), displaying an IC50 of 54 nM for hHIF-PHD2. Its potential as a therapeutic agent for renal anemia is highly promising.</p>Fórmula:C17H12Cl2N6O3Cor e Forma:SolidPeso molecular:419.22YF-2 hydrochloride
CAS:<p>YF-2 hydrochloride is a potent histone acetyltransferase activator that exhibits high selectivity and can pass through the blood-brain barrier. It specifically acetylates H3 in the hippocampus, with EC50 values of 2.75 μM, 29.04 μM, and 49.31 μM for CBP, PCAF, and GCN5, respectively. Notably, it does not affect HDAC activity. Moreover, YF-2 hydrochloride demonstrates promising anti-cancer and anti-Alzheimer's disease properties.</p>Fórmula:C20H23Cl2F3N2O3Cor e Forma:SolidPeso molecular:467.31Amredobresib
CAS:Amredobresib is a potent BET inhibitor that impedes the interaction between bromodomains and acetylated lysines on histone H3 and H4, thereby serving as crucial regulators of gene transcription. It proves valuable in the investigation of acute myeloid leukemia (AML) and cancer.Fórmula:C26H29N9Cor e Forma:SolidPeso molecular:467.581PLK1-IN-6
<p>PLK1-IN-6: potent, selective PLK1 inhibitor, IC50 = 0.45 nM, hinders cancer cell growth.</p>Fórmula:C28H37N9O3Cor e Forma:SolidPeso molecular:547.65PARP1 Protein, Human, Recombinant (His)
<p>PARP Protein, Human, Recombinant (His) is expressed in Baculovirus insect cells with His tag.</p>Pureza:94.1%Cor e Forma:Lyophilized PowderPeso molecular:114.5 kDa (predicted); 100-110 kDa (reducing conditions)Desidustat
CAS:<p>Desidustat is an inhibitor of HIF hydroxylase.</p>Fórmula:C16H16N2O6Pureza:98%Cor e Forma:SolidPeso molecular:332.31CTB
CAS:<p>CTB (Cholera Toxin B subunit) is an activator of p300 histone acetyltransferase and induces apoptosis in MCF-7 cells.</p>Fórmula:C16H13ClF3NO2Pureza:99.82%Cor e Forma:SolidPeso molecular:343.73PF-03814735
CAS:PF-03814735 is a novel, potent and reversible inhibitor of Aurora A/B with IC50of 0.8 nM/5 nM, is less potent to Flt3, FAK, TrkA, and minimally active to Met and FGFR1. Phase 1.Fórmula:C23H25F3N6O2Pureza:98%Cor e Forma:SolidPeso molecular:474.48Bisindolylmaleimide I HCl
CAS:Bisindolylmaleimide I HCl is a specific ATP-competitive PKC inhibitor.Fórmula:C25H25ClN4O2Pureza:98%Cor e Forma:SolidPeso molecular:448.95BET-IN-15
CAS:<p>BET-IN-15 (compound 1) is a potent, orally active inhibitor of BET, demonstrating inhibitory IC50 values of 0.64 nM for BRD4-BD1 and 0.25 nM for BRD4-BD2.</p>Fórmula:C21H18F2N4O3SPureza:98%Cor e Forma:SolidPeso molecular:444.45Ref: TM-T79167
Produto descontinuadoAMPK activator C2
CAS:AMPK activator C2 is an AMPK allosteric activator.Fórmula:C7H6NO6PPureza:98%Cor e Forma:SolidPeso molecular:231.1JAK2-IN-9
CAS:<p>Compound A8, known as JAK2-IN-9, is a selective JAK2 inhibitor with an IC50 of 5 nM.</p>Fórmula:C20H24N6O2SPureza:98%Cor e Forma:SolidPeso molecular:412.51Ref: TM-T79581
Produto descontinuadoBLL5 Maleate
CAS:<p>BLL5 Maleate is a first-in-class selective PRMT5 inhibitor, it blocks EBV-driven B lymphocyte transformation and survival while leaving normal B cells unaffected.</p>Fórmula:C21H21N3Pureza:98%Cor e Forma:SolidPeso molecular:315.41JAK1-IN-11
CAS:<p>JAK1-IN-11 (compound 11) serves as a potent inhibitor of Janus kinases, exhibiting nanomolar inhibitory concentrations with IC50 values of 0.02 nM (JAK1) and 0.</p>Fórmula:C26H36N6O4SPureza:98%Cor e Forma:SolidPeso molecular:528.67Antitumor agent-104
CAS:<p>Antitumor Agent-104 (Compound 9) serves as an antineoplastic by impeding DNA repair mechanisms in tumor cells, primarily through the inhibition of PARP1 enzyme</p>Fórmula:C31H33FN6O3Pureza:98%Cor e Forma:SolidPeso molecular:556.63STAT3-IN-18
CAS:<p>STAT3-IN-18 (compound SPP), a platinum (IV) complex featuring an axial ligand from sandalwood, suppresses the JAK2-STAT3 pathway in breast cancer (BC) cells and</p>Fórmula:C18H24Cl2N2O6PtPureza:98%Cor e Forma:SolidPeso molecular:630.38BBDDL2059
CAS:<p>BBDDL2059 is a selective covalent inhibitor targeting EZH2, exhibiting an IC50 of 1.5 nM against the EZH2-Y641F mutant.</p>Fórmula:C27H36N4O4SPureza:98%Cor e Forma:SolidPeso molecular:512.66Ref: TM-T79200
Produto descontinuadoLerzeparib
CAS:<p>Lerzeparib is a PARP (ADP-ribose polymerase) inhibitor that exhibits antineoplastic activity [1].</p>Fórmula:C21H20FN3O2Pureza:98%Cor e Forma:SolidPeso molecular:365.4Igermetostat
CAS:<p>Igermetostat, an EZH2 inhibitor, is utilized both in vivo and in vitro for cancer research [1].</p>Fórmula:C32H46N4O4Pureza:98%Cor e Forma:SolidPeso molecular:550.73DPP
CAS:<p>DPP, a Platinum(IV) complex with a pterostilbene-derived axial ligand, inhibits the JAK2-STAT3 pathway in breast cancer (BC) cells, demonstrating</p>Fórmula:C36H40Cl2N2O10PtPureza:98%Cor e Forma:SolidPeso molecular:926.7JAK1-IN-10
CAS:<p>JAK1-IN-10 (compound 9), a cyano-substituted cyclic hydrazine derivative, functions as a potent and selective inhibitor of JAK1 [1].</p>Fórmula:C15H17N7Pureza:98%Cor e Forma:SolidPeso molecular:295.34JAK-IN-27
CAS:<p>JAK-IN-27, also known as compound 1, is an orally active, potent inhibitor of the JAKS family kinases, displaying inhibitory concentrations (IC50s) of 3.0 nM</p>Fórmula:C20H21F2N7OPureza:98%Cor e Forma:SolidPeso molecular:413.42BAZ2-ICR
CAS:<p>BAZ2-ICR is an epigenetic chemical probe and it also is a potent, selective, cell active and orally active BAZ2A/B bromodomains inhibitor with IC50s of 130 nM and 180 nM, and Kds of 109 nM and 170 nM, respectively. BAZ2-ICR shows 10-15-fold selectivity for binding BAZ2A/B over CECR2 and >100-fold selectivity over all other bromodomains.</p>Fórmula:C20H19N7Pureza:98%Cor e Forma:SolidPeso molecular:357.41BET-IN-14
CAS:<p>BET-IN-14 is a pan BET inhibitor with an IC50 of 5.35 nM, demonstrating oral activity and anticancer properties [1].</p>Fórmula:C30H37N7O2Pureza:98%Cor e Forma:SolidPeso molecular:527.66JAK-IN-34
CAS:<p>JAK-IN-34 (compound 11n) is a potent inhibitor of Janus kinases (JAKs), demonstrating IC50 values of 0.40 nM for JAK1, 0.83 nM for JAK2, 2.10 nM for JAK3,</p>Fórmula:C27H26N6OPureza:98%Cor e Forma:SolidPeso molecular:450.53BB-Cl-Amidine hydrochloride
CAS:BB-Cl-Amidine hydrochloride is an inhibitor of peptidylarginine deminase (PAD) [1].Fórmula:C26H27Cl2N5OPureza:98%Cor e Forma:SolidPeso molecular:496.43PARP7-IN-16 free base
CAS:<p>PARP7-IN-16 free base is the freebase form of PARP7-IN-16. As a selective oral inhibitor of PARP-1/2/7, it demonstrates IC50 values of 0.94, 0.87, and 0.21 nM, respectively. This compound is utilized in the research of breast and prostate cancer.</p>Fórmula:C25H27FN4O4Cor e Forma:SolidPeso molecular:466.50Ref: TM-T200703
Produto descontinuadoBET BD2-IN-3
CAS:<p>BET BD2-IN-3 (compound I-58), a BET inhibitor specifically targeting the BD2 domain, can be radiolabeled with [11C] for use in positron emission tomography (PET) imaging. PET studies with [11C]BD2-IN-3 in mice have demonstrated appropriate biodistribution in peripheral organs and tissues.</p>Fórmula:C29H30N4OCor e Forma:SolidPeso molecular:450.58
